Autobio Diagnostics Co., Ltd. (SHA: 603658)

Market Cap	26.60B
Revenue (ttm)	4.58B
Net Income (ttm)	1.27B
Shares Out	572.12M
EPS (ttm)	2.20
PE Ratio	21.13
Forward PE	19.13
Dividend	1.05 (2.24%)
Ex-Dividend Date	Jun 5, 2024

Volume	3,941,251
Open	45.89
Previous Close	45.72
Day's Range	45.76 - 47.10
52-Week Range	37.56 - 66.36
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products. It develops immunoassay, biochemistry, and microbiology products, as well as reagents; and instruments, as well as medical laboratory solutions. The company’s immunoassay products AutoLumo A1860 that provides user experience for small and medium size labs; an automated chemiluminescence immunoassay analyzer; AutoLumo A2000 Plus, an automatic chemiluminescence immunoassay analyzer; AutoLumo A1000, an au...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,539
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2023, Autobio Diagnostics's revenue was 4.44 billion, an increase of 0.05% compared to the previous year's 4.44 billion. Earnings were 1.22 billion, an increase of 4.28%.